Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 3Mesothelioma 3Mesothelioma, Malignant 2Unspecified Adult Solid Tumor 1Thymoma 1Solid Tumor Cancer 1Small Cell Lung Carcinoma 1Seminoma 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma, Endometrial Stromal 1Rhabdomyosarcoma, Embryonal 1Relapsed Pediatric Solid Tumor 1Primary Myelofibrosis 1Pleural Neoplasms 1Osteosarcoma 1Neurofibrosarcoma 1Multiple Myeloma 1Metastatic Solid Tumors. 1Melanoma 1Mastocytosis 1Malignant mesenchymal tumor 1Liposarcoma 1Leukemia, Mast-Cell 1Leiomyosarcoma 1Hypereosinophilic Syndrome 1Hemangiosarcoma 1Hemangiopericytoma 1Fibroma 1Dermatofibrosarcoma 1

Interventions

ispinesib 2trifluridine tipiracil drug combination 1trametinib 1tipiracil 1irinotecan sucrosofate 1Vincristine 1Trifluridine 1Temozolomide 1TP protocol 1SB 743921 1Pemetrexed 1Paclitaxel 1PE regimen 1Interleukin-18 1Immunotherapy 1Imatinib Mesylate 1Exercise Therapy 1Docetaxel 1Cisplatin 1Carboplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Tumor Cancer × Imatinib Mesylate × Other solid neoplasm × Clear all
NCT06962254 2025-05-08

Imatinib and Trametinib for KRAS-mutated Solid Tumor

China Medical University Hospital

Phase 1 Recruiting
10 enrolled
Other solid neoplasm

Solid Tumor Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡